

K190196 % Cynthia Merrell Vice-President QA &RA VitalConnect Inc. Contact Address

Re: K190196

Trade/Device Name: VitalPatch® Biosensor Regulation Number: 21 CFR 870.2910

Regulation Name: Radiofrequency Physiological Signal Transmitter And Receiver

Regulatory Class: Class II Product Code: DRG Dated: June 7, 2019 Received: April 9, 2019

## Dear Cynthia Merrell:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at <a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm">https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm</a> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's

requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see <a href="https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products">https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products</a>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <a href="https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems">https://www.fda.gov/medical-device-problems</a>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<a href="https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance">https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance</a>) and CDRH Learn (<a href="https://www.fda.gov/training-and-continuing-education/cdrh-learn">https://www.fda.gov/training-and-continuing-education/cdrh-learn</a>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<a href="https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice">https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice">https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice</a>) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

For Matthew Hillebrenner
Deputy Director
Division of Cardiac Electrophysiology, Diagnostics
and Monitoring Devices
Office of Cardiovascular Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

## DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

## **Indications for Use**

510(k) Number (if known)

Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement below.

K190196	
Device Name VitalPatch Biosensor	
Indications for Use (Describe) The VitalConnect Platform is a wireless remote monitoring syst continuous collection of physiological data in home and healther electrocardiography (ECG), heart rate variability, R-R interval, activity (including step count), and posture (body position relativity) (including step count), and position relativity (including step count), and position relativity (including step	are settings. This can include heart rate, respiratory rate, body temperature, skin temperature, ve to gravity including fall). Data are transmitted as. The VitalConnect Platform can include the ability to side selected parameters.  18 years of age or older as a general patient monitor, to nect Platform are intended for use by healthcare
Type of Use (Select one or both, as applicable)	
Prescription Use (Part 21 CFR 801 Subpart D)	Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

## \*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

## 510(k) SUMMARY

This summary of 510(k) safety and effectiveness information is submitted in accordance with the requirements of 21 CFR §807.92:

#### I. SUBMITTER

VitalConnect, Inc.

Address 224 Airport Parkway, Suite 300

City, State, Zip USA San Jose, CA, 95110, USA

Tel: +1.408.963.4600 Fax: +1.408.963.2828

Contact Person: Cynthia Merrell, VP QA&RA

Date Prepared: April 4, 2019

#### II. DEVICE

Name of Device: VitalPatch Biosensor

Classification Name: Cardiovascular Monitoring Devices 21 Regulation: CFR §870.2910, 21 CFR 870.1025

Regulatory Class II

Product Classification Code: DRG, DSI, MHX

## III. PREDICATE DEVICE

Predicate Manufacturer: Vital Connect, Inc.

Predicate Trade Name: VitalPatch® VitalConnect Platform

Predicate 510(k): K183078

No reference devices were used in this submission.

#### IV. DEVICE DESCRIPTION

VitalPatch is a wearable biosensor designed to measure a patient's vital signs, including heart rate, electrocardiography (ECG), heart rate variability, R-R interval, respiratory rate, skin temperature, activity (including step count), and posture (body position relative to gravity including fall). VitalPatch was most recently cleared in K183078.

The following modifications are proposed for the VitalPatch wearable biosensors:

• Increasing the duration for use from 5 days (120 hours) to 7 days (168 hours). This includes a minor software change and minor changes to the IFU.

All other vital signs, including heart rate, electrocardiography (ECG), heart rate variability, R-R interval, respiratory rate, body temperature, skin temperature, activity (including step count), and posture (body position relative to gravity including fall) cleared in K183078 remain the same.

## V. INDICATIONS FOR USE

The VitalConnect Platform is a wireless remote monitoring system intended for use by healthcare professionals for continuous collection of physiological data in home and healthcare settings. This can include heart rate, electrocardiography (ECG), heart rate variability, R-R interval, respiratory rate, body temperature, skin temperature, activity (including step count), and posture (body position relative to gravity including fall). Data are transmitted wirelessly from the VitalConnect Sensor for storage and analysis. The VitalConnect Platform can include the ability to notify healthcare professionals when physiological data fall outside selected parameters.

The device is intended for use on general care patients who are 18 years of age or older as a general patient monitor, to provide physiological information. The data from the VitalConnect Platform are intended for use by healthcare professionals as an aid to diagnosis and treatment. The device is not intended for use on critical care patients.

# VI. COMPARISON OF TECHNOLOGICAL CHARACTERISTICS WITH THE PREDICATE DEVCE

The intended use and technological features of the proposed Vital Connect Platform do not substantially differ from the legally marketed predicate device. The Vital Connect Platform and the predicate device have substantially equivalent intended uses and methods of operation.

Table 1 Comparison of Indications for Use (the indications for use are identical)

#### Predicate (K183078)

The VitalConnect Platform is a wireless remote monitoring system intended for use by healthcare professionals for continuous collection of physiological data in home and healthcare settings. This can include heart rate, electrocardiography (ECG), heart rate variability, R-R interval, respiratory rate, body temperature, skin temperature, activity (including step count), and posture (body position relative to gravity including fall). Data are transmitted wirelessly from the VitalConnect Sensor for storage and analysis. The VitalConnect Platform can include the ability to notify healthcare professionals when physiological data fall outside selected parameters.

The device is intended for use on general care patients who are 18 years of age or older as a general patient monitor, to provide physiological information. The data from the VitalConnect Platform are intended for use by healthcare professionals as an aid to diagnosis and treatment. The device is not intended for use on critical care patients.

## **Subject Device**

The VitalConnect Platform is a wireless remote monitoring system intended for use by healthcare professionals for continuous collection of physiological data in home and healthcare settings. This can include heart rate, electrocardiography (ECG), heart rate variability, R-R interval, respiratory rate, body temperature, skin temperature, activity (including step count), and posture (body position relative to gravity including fall). Data are transmitted wirelessly from the VitalConnect Sensor for storage and analysis. The VitalConnect Platform can include the ability to notify healthcare professionals when physiological data fall outside selected parameters.

The device is intended for use on general care patients who are 18 years of age or older as a general patient monitor, to provide physiological information. The data from the VitalConnect Platform are intended for use by healthcare professionals as an aid to diagnosis and treatment. The device is not intended for use on critical care patients.

Table 2 Size Comparison of the adhesive patch

Dimension	Predicate (K183078)	Subject Device
Length	115 mm	120 mm
Width	35.6 mm	40.6 mm
Height	7.5 mm	9.4 mm

Table 3 Component Comparison of the Predicate and Subject Devices

Component	Predicate (K183078)	Proposed Device
ECG electrodes	Allow the recording of a single-lead bipolar ECG at a sampling rate of 125 Hz	Identical
Skin Thermistor	Mounted on the patch. Designed to monitor skin temperatures when the patch is attached to the skin.	Identical
Ambient Thermistor	Designed to monitor ambient temperature to more accurately calculate body temperature using the skin temperature input.	Identical
Flexible Assembly	Provides a connection between the ECG electrodes, thermistors and patch electronics. The flexible circuit is sealed within the patch.	Identical
Firmware	Version 3.1.0.1 to support functions listed in Table 4 for Predicate (K183078)	Version 3.2.1.0 of firmware fixes a bug and allows configuration for 120-hour patch life timer or 168-hour patch-life timer.

## **Table 4 – Device Performance Characteristics Comparison**

Performance Characteristic	Predicate (K183078)	Proposed Device
Wireless Transmission	Bluetooth Low Energy (BT4.1) technology	Identical
Data encryption	Advanced Encryption Standard-CCM mode	Identical
Radio Frequency	2.4GHz ISM band FCC Part 15 Complied	Identical

ECG Dynamic Range	The Sensor electrodes make contact with the skin to measure the differential voltage generated from the heart. The resulting analog ECG waveform is digitized so that the data can be streamed to a display or recording device.  Range: -10mV to +10mV	Identical
Heart Rate (stationary and ambulatory)	Heart rate is measured and calculated in Beats Per Minute (BPM) both for stationary and ambulatory use. Range: 30 - 200 BPM	Identical
Respiratory Rate	From a combination of ECG and tri-axial accelerometer sensor signals, the Vital Connect Sensor can accurately measure the respiratory rate of the person, irrespective of whether the person is stationary or ambulatory.  Range: 10-30 breaths per minute	Identical
Skin Temperature	Using a thermistor sensor on the Patch, which is in close proximity to the skin, the Vital Connect Sensor accurately measures the temperature of the skin, reporting the temperature in degrees Centigrade. A known quantity of current generated by the sensor is converted to a voltage that is accurately matched to skin temperature.  Range: 15°C - 50 °C (61°F - 113°F)	Identical
Ambient Temperature	Using an additional thermistor sensor on the Patch, which is away from the skin, the VitalConnect Biosensor accurately measures patch ambient temperature, reporting the temperature in degrees Centigrade. A known quantity of current generated by the sensor is converted to a voltage that is accurately matched to the ambient temperature.  Range: 15°C - 50 °C (61°F - 113°F)	Identical
Body Temperature	A calculated value as a function of the skin and ambient temperatures.  Range: 32°C - 42°C	Identical
Fall Detection	Using a tri-axial accelerometer and digital signal processing techniques, the Vital Connect Sensor detects falls while minimizing false notifications.  Range: Fall or No Fall	Identical

Step Count	The Vital Connect Sensor also uses the triaxial accelerometer to compute step count. As the person walks, the Vital Connect Sensor is capable of distinguishing steps from other movements. The detected steps are accumulated to provide an accurate step count.  Range: 0 - 65535 steps	Identical
Posture Detection	Using the built-in tri-axial accelerometer, the Vital Connect Sensor can determine the posture of the person and provide wireless real-time updates to a central server.  Postures detected include lying down, upright, walking, running and leaning.	Identical
R-R Interval	The R-R interval is the measurement of the interval from the R wave peak of one QRS complex to the next R-wave peak on the electrocardiogram. The device has enhanced QRS performance during motion.	Identical
Heart Rate Variability	HRV quantifies the variation in the beat-to-beat interval time series obtained from the ECG waveform. Using advanced signal processing algorithms, the Sensor detects each QRS peak with high temporal accuracy. Measurement of the R wave to R wave (RR) interval allows short and long-term variability analysis to determine analytics such as mean, median, standard deviation, frequency content, etc.	Identical
Low Power Mode	When patch is off the body, to conserve battery power, the processor goes into a low power mode, resulting in reduced current draw.	Identical

## VII. PERFORMANCE DATA

Verification and validation activities established the safety and performance characteristics of the proposed device with respect to the predicate. The following performance data have been provided in support of the substantial equivalence determination:

## **Sterilization & Shelf-life Testing**

The Vital Connect Platform is provided non-sterile, and therefore sterilization data is not provided. Accelerated aging data was provided to support a shelf-life of 9 months as previously cleared.

## **Biocompatibility Testing**

Biocompatibility testing, previously conducted, included in-vitro cytotoxicity, irritation and sensitization, according to the recommendations of ISO 10993-1:2009, Biological evaluation of medical devices – Part 1: Evaluation and testing.

## Electrical safety and electromagnetic compatibility (EMC)

Electrical safety and EMC testing were conducted on the VitalPatch. The device complies with the IEC 60601-1, IEC 60601-1-11, IEC 60601-2-25, and the IEC 60601-2-47 standards for safety. The device also complies with the IEC 60601-1-2 standard for EMC, IEC/TS 62657-2 and FCC CRF47 Part 15 Subpart C standards for wireless communication.

## **Software Verification and Validation Testing**

Software verification and validation testing was conducted, and documentation is provided as recommended by FDA's Guidance for Industry and FDA Staff, Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices. The software for this device is determined as a "moderate" level of concern because a failure or latent flaw could lead to a minor injury to the patient through incorrect information or through the action of the care provider.

## **Benchtop & Simulated Use Testing**

The following testing was provided to demonstrate the safe and effective performance of the subject device for 168 hours:

- Wear Duration Testing
- Battery operating life testing
- EOL Detection after 168 hours

## **Animal Study**

Animal performance testing was not required to demonstrate safety and effectiveness of the device.

#### **Clinical Studies**

Clinical testing was not required to demonstrate the safety and effectiveness of the VitalPatch. Instead, substantial equivalence is based upon benchtop performance testing.

#### VIII. CONCLUSIONS

The subject device is substantially equivalent in design and intended use to the predicate device. Any differences between the subject device and the predicate device have no significant influence on safety or effectiveness as established through performance testing. Therefore, the subject device raises no new issues of safety or effectiveness from the predicate device.